Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in…
The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Instructions for uploading your PowerPoint presentation and survey: The PPT attachment needs to be the first node under the report (i.e., it should appear before your survey).Name the PPT in the…
MARKET OUTLOOK Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are among the most common and serious infections in the hospital setting. HABP/VABP…
The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD). The MDD treatment armamentarium is becoming…
No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized by sicca symptoms, which are caused by chronic inflammation…
Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors have entered the…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease…
Market Outlook Targeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule…
MARKET OUTLOOK Sarcoidosis is an inflammatory disease of unclear etiology. It is characterized by tissue infiltration of granulomas, most commonly into the lung and lymph nodes, but the skin,…
Epidemiology of Pediatric Ischemic Stroke in EU5. Table of Contents: 1. Stroke Literature Review Data – EU5 2. Stroke Literature Review Data – Non-EU5 3. Stroke Hospital Discharge Review…
MARKET OUTLOOK Following approval by the FDA in 2015, AbbVie’s Humira (adalimumab) became (and remains) the only approved therapy for the treatment of hidradenitis suppurativa. Humira is…